Compare JAZZ & PKX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JAZZ | PKX |
|---|---|---|
| Founded | 2003 | 1968 |
| Country | Ireland | South Korea |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Steel/Iron Ore |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1B | 15.0B |
| IPO Year | 2007 | 1998 |
| Metric | JAZZ | PKX |
|---|---|---|
| Price | $242.66 | $48.45 |
| Analyst Decision | Buy | |
| Analyst Count | 22 | 0 |
| Target Price | ★ $297.50 | N/A |
| AVG Volume (30 Days) | ★ 691.1K | 242.1K |
| Earning Date | 11-02-2026 | 11-02-2026 |
| Dividend Yield | N/A | ★ 2.50% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $1,618,693,000.00 | N/A |
| Revenue This Year | $12.68 | $7.35 |
| Revenue Next Year | $5.34 | $2.43 |
| P/E Ratio | $6,014.25 | ★ $42.95 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $156.95 | $47.63 |
| 52 Week High | $266.38 | $92.40 |
| Indicator | JAZZ | PKX |
|---|---|---|
| Relative Strength Index (RSI) | 61.11 | 39.02 |
| Support Level | $236.70 | N/A |
| Resistance Level | $250.49 | $59.26 |
| Average True Range (ATR) | 7.43 | 1.26 |
| MACD | 2.04 | 0.03 |
| Stochastic Oscillator | 81.96 | 14.82 |
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
POSCO Holdings Inc is a holding company operating through its subsidiaries. Its business is divided into segments, with the Steel segment generating the majority of revenue from the manufacture and sale of steel products. The Infrastructure segment includes trading, construction, and logistics and system integration activities. The Rechargeable Battery Materials segment focuses on EV battery materials such as lithium, nickel, and cathode and anode materials. The Others segment includes the controlling company and investment business. Geographically, the Group generates majority of its revenue from Asia (excluding China and Japan).